There is no reason to think that Missling has seriously considered a Covid testing program. The company has a number of trials underway with the attendant data analysis and agency submissions.
The company has murine testing to support everything it has done so far. There has been no murine testing of 2-73 for Covid that I am aware of. That makes such a trial a much higher risk of failure than the present trials. Why would the company take such a chance which if it failed would significantly weaken the momentum that is building for 2-73 as a paradigm changer in the CNS space.
Market Data 
Markets 
AI
